These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18977050)

  • 1. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
    Giro C; Berger B; Bölke E; Ciernik IF; Duprez F; Locati L; Maillard S; Ozsahin M; Pfeffer R; Robertson AG; Langendijk JA; Budach W
    Radiother Oncol; 2009 Feb; 90(2):166-71. PubMed ID: 18977050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
    Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT.
    Studer G; Brown M; Salgueiro EB; Schmückle H; Romancuk N; Winkler G; Lee SJ; Sträuli A; Kissling B; Dummer R; Glanzmann C
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):110-7. PubMed ID: 20732757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab.
    Bölke E; Gerber PA; Lammering G; Peiper M; Müller-Homey A; Pape H; Giro C; Matuschek C; Bruch-Gerharz D; Hoffmann TK; Gripp S; Homey B; Budach W
    Strahlenther Onkol; 2008 Feb; 184(2):105-10. PubMed ID: 18259703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab.
    Koutcher LD; Wolden S; Lee N
    Am J Clin Oncol; 2009 Oct; 32(5):472-6. PubMed ID: 19487913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
    Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer.
    Pryor DI; Porceddu SV; Burmeister BH; Guminski A; Thomson DB; Shepherdson K; Poulsen M
    Radiother Oncol; 2009 Feb; 90(2):172-6. PubMed ID: 18976827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe cutaneous reaction during radiation therapy with concurrent cetuximab.
    Budach W; Bölke E; Homey B
    N Engl J Med; 2007 Aug; 357(5):514-5. PubMed ID: 17671265
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
    Bernier J; Russi EG; Homey B; Merlano MC; Mesía R; Peyrade F; Budach W
    Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy.
    Cabezón-Gutiérrez L; Khosravi-Shahi P; Escobar-Álvarez Y
    Oral Oncol; 2012 Apr; 48(4):293-7. PubMed ID: 22137799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
    Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
    Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
    Prosnitz RG; Yao B; Farrell CL; Clough R; Brizel DM
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1087-95. PubMed ID: 15752888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
    Curran D; Giralt J; Harari PM; Ang KK; Cohen RB; Kies MS; Jassem J; Baselga J; Rowinsky EK; Amellal N; Comte S; Bonner JA
    J Clin Oncol; 2007 Jun; 25(16):2191-7. PubMed ID: 17538164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. StatBite: Radiation therapy plus cetuximab: skin reactions from 71 head and neck cancer patients from 11 institutions in Europe.
    J Natl Cancer Inst; 2010 Jan; 102(2):75. PubMed ID: 20054017
    [No Abstract]   [Full Text] [Related]  

  • 17. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
    Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
    J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas.
    Clin Adv Hematol Oncol; 2007 Feb; 5(2):79-81. PubMed ID: 17344795
    [No Abstract]   [Full Text] [Related]  

  • 19. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
    Teoh DC; Rodger S; Say J; Hartley A
    Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.